IMC-002
Phase 2Small molecule
IMC-002 is one of 110 small molecule programs targeting Advanced Cancer. It is currently in Phase 2.
3
Indications
4
Total Trials
3
Active Trials
109
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
134 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Medrol
PfizerPhase 3
Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Gazyva
RochePhase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Ianalumab
NovartisPhase 3
Glucocorticoid
AbbViePhase 3
Namenda
AbbViePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma1 trial
Advanced Cancer1 trial
Neuromyelitis Optica1 trial
A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients
Not yet recruiting·IImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.·Phase 1/2·NCT06557174·116 enrolled
Systemic Lupus Erythematosus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMC-002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmuneOncia Therapeutics Inc.